Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma

Transfusion

Volumn 55, Issue 11, 2015, Pages 2770-

  Hannon, Judith L ^a   Clarke, Gwen ^a  

^a CANADIAN BLOOD SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; DARATUMUMAB; DITHIOTHREITOL; HEMOGLOBIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G1; MACROGOL; MONOCLONAL ANTIBODY;

BLOOD TRANSFUSION; COOMBS TEST; ERYTHROCYTE; GENOTYPE; HUMAN; LETTER; MULTIPLE MYELOMA; PHENOTYPE; BLOOD GROUP TYPING; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; BLOOD GROUPING AND CROSSMATCHING; ERYTHROCYTES; HUMANS;

EID: 84947087440     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13267     Document Type: Letter

References (4)

1. Chapuy CI, Nicholson RT, Aguad MD, et al., Resolving the daratumumab interference with blood compatibility testing. Transfusion 2015; 55: 1545-54.
2. De Weers M, Tai Y, van der Veer MS, et al., Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840-8.
3. Sapatnekar S, Figueroa PI., How do we use molecular red blood cell antigen typing to supplement pretransfusion testing? Transfusion 2014; 54: 1452-8.
4. Casas J, Freidman DF, Jackson T, et al., Changing practice: red blood cell typing by molecular methods for patients with sickle cell disease. Transfusion 2015; 55: 1388-93.